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Human diazepam binding inhibitor (OBI) was originally 
isolated from the brain and subsequently found to be present 
in several peripheral tissues. The various physiologic effects 
recently attributed to OBI include acting as an endogenous 
ligand for the central and peripheral (mitochondrial) benzo-
diazepine receptors. The present work provides, for the first 
time, evidence of OBI immunoreactivity in skin. OBI im-
munoreactivity was found in the epidermis, in the eccrine 
sweat and in sebaceous glands. Ultrastructurally, OBI was 
A lthough benzodiazepines are in extensive clinical use for their well-known anxiolytic, hypnotic, and anti-convulsant activities, recent experimental evidence has shown that they may also have other functions, such as the regulation of steroid synthesis, neoplastic 
growth, and the immune response [1-3]. Whereas their clinical use 
is based on a central nervous system action mediated through the 
classic central benzodiazepine receptor (CBR) sites located on the 
GABA" receptor complex, the experiments concerned are based on 
interaction with a second class of benzodiazepine receptors, called 
peripheral or mitochondrial benzodiazepine receptors (MER) [4,5]. 
MERs playa central role in the regulation of lipid and steroid 
synthesis and are widely distributed in peripheral tissues including 
skin [6,7] . 
Recently an endogenous polypeptide capable of displacing ben-
zodiazepine binding to both CBR and MER has been purified from 
the brain and liver of different species and designated as diazepam 
binding inhibitor (DBI) (see [8,9]). Physiologic effects recently at-
tributed to DEI include regulation of GABA" and MER receptors 
[10,11], binding to acyl-coenzyme A (acyl-CoA) [12,13], termina-
tion of long-chain fatty acid synthesis [14], stimulation of choles-
terol to the inner mitochondrial membrane [3,15]' inhibition of 
glucose-induced insulin release from pancreatic islets [16] , and 
stimulation of mitochondrial steroidogenesis [3,15,17]. 
Human DBI is an 86-amino acid polypeptide that has been puri-
fied to homogeneity from human brain [18,19] and the human gene 
has been localized to chromosome 2, within the 2q12-21 region 
[20] . Non-neuronal DEI is highly concentrated in liver, kidney, and 
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dist.ributed throu~hou.t t~e cytoplasm. Although the physio-
logIc role of OBI m skm IS unknown, our results indicate that 
OBI may serve as an endogenous ligand for mitochondrial 
benzodiazepine receptors. Its activity could be related to the 
regulation of lipid and cholesterol synt!lesis in keratinocytes 
and sebaceous glands and to the secretIon of sweat in sweat 
glands. Key words: diazepam binding inhibitor/benzodiaze_ 
pine receptors/immunocytochemistry/human skin/lipid 
synthesis.] Invest Dermato/101 :800-803, 1993 
endocrine tissues [21]. but there is no previous report on the locali-
zation or distribution of DB I in skin. Recent observations that MER 
is also localized in skin [6] and that DEI stimulates steroid synthesis 
via MER .could be o~ special i~terest in studies of the physiologic and 
pathologiC metabolism of sk1l1. These recent findings prompted us 
to investigate the distribution and localization of DEI-like immu-
noreactivity (DBI-LI) in human skin. 
MATERIALS AND METHODS 
Tissue Preparation Skin samples were obtained from three male and four 
female. patients ~ged 18 - 82 years. The Ratients were operated on for benign 
or mahgnant s~m tumors or for cosmetic reasons. Only healthy skin pieces 
were mcluded m the present study. The samples were taken from the skin of 
face, neck, upper arm, back, or abdomen and immersed in 4% para formal de-
hyde containing 0.3% picric acid in 0.1 M phosphate buffer, pH 7.3, for 
2-4 h at 4 · C. Before the immunohistochemical staining, the specimens 
were washed in phosphate-buffered saline (PBS) for 48 h, embedded in 
OCT-Tissue-Tek II (Miles Inc., Elkhart,IN), and cuton a cryostat at 10 /lIn. 
The sections were stored at -70 · C until use. 
P.rin;ta~ ~tibody A polyclonal antiserum against human diazepam 
bmdmg mhlbltor (OBI) was used. The antIserum was raised in rabbits 
against human OBI, extracted, and purified from human postmortem brain. 
The characterization of h-DBI antiserum is described in detail by Ferrem 
et al [11]. 
Immunohistochemistry For the demonstration of OBI immunoreactiv_ 
ity the sections were incubated with h-DBI antiserum (1: 1000) in PBS 
containing 1% IGS for 24 h. The staining procedure has been previously 
described in detail by Alho et at [22,23] . The sections were mounted Ut 
Aquamount (Gurr, BDH, Dorset, U.K.) and observed with a Nikon Micro-
phot-FXA light microscope. The immunohistochemical specificity Was 
verified by incubating the sections either with preimmune serum instead of 
the specific antiserum or by preabsorbing the OBI antiserum with OBI 
peptide (1.5 11M). 
Electron Microscopy After the tissue preparation and immunohisto-
chemical staining procedure described above, a conventional electron mi. 
croscopy method was employed. Briefly, the sections were postfixed ",;th 
2.5% glutaraldehyde in 0.1 M PBS for 1 h at room temperature, posts tained 
with ice-cold 2% osmium tetroxide in 0.1 M PBS for 1 h, dehydrated in 
0022-202X/93/S06.00 Copyright © 1993 by The Society for Investigative Dermatology, Inc. 
800 
VOL. 101, NO. 6 DECEMBER 1993 
a 
b 
c 
-
DBI IMMUNOREACTIVITY IN HUMAN SKlN 801 
Figure 1. DDI-LI in the human epidermis and sebaceous gland as demon-
strated with the immunoperoxidase method. a) In epidermis an intense 
staining is seen in the granular cell layer (arrowhead) and in the upper parts of 
the spinous cell layer but not in the basal cell layer (asterisks) or keratin layer 
(opell arrow). b) A control section incubated with preabsorbed DBI anti-
serum; no specific staining is seen. c) In sebaceous gland the most intense 
staining is seen in the outer sebaceous cells (arrowheads). Bar, 50 jim . 
ethanol, and, via propylene oxide, embedded with Epon and cut into ul-
trathin sections and counterstained with lead citrate only (0.2%). 
RESULTS 
The distribution ofDBI immunoreactivity (DBI-LI) was similar in 
all the tissue samples studied. No differences were noted in the 
staining intensity or distribution of DBI-LI between males and fe-
males or between different skin regions. In the epidermis keratino-
cytes in the upper part of the spinous layer and throughout the 
granular cell layer showed DBI-LI (Fig 1a) The intensity of the 
immunoreaction increased in the more superficial cell layers. How-
ever, no DBI-LI was seen in the corneal layer (Fig 1a). The immu-
noreaction was seen in the cytoplasm of the keratinocytes, and the 
nuclei were unstained. Intense DBI-LI was also seen in the eccrine 
sweat glands. Cytoplasmic staining was seen in the secondary coils 
of the glands but not in the ductal parts of the glands (Fig 20,b). 
DBI-LI was also demonstrated in the sebaceous glands. Immunore-
activiry was seen in the cytoplasm of sebaceous cells, whereas the 
lipid droplets as well as the cell nuclei were unstained (Fig lc). None 
of the other dermal structures showed any DBI-LI. 
No DBI-LI could be demonstrated in the control sections incu-
bated with primary antibody preabsorbed with DBI peptide (Fig lb) 
or with the preimmune serum. 
In the eccrine sweat gland DBI-LI was localized, using the elec-
tron microscopy (EM) technique, in the clear cells of the secretory 
coil. No immunostainillg was observed in the dark cells of secretory 
coil or in any other cells of the ductal parts of the glands (Fig 30) . 
DBI was distributed throughout the cytoplasm. Precipitates were 
seen in Golgi apparatus and mitochondria. A similar distribution of 
DBI-LI throughout the cytoplasm was observed in the keratino-
cytes and in the secretory cells of sebaceous glands (Fig 3b). 
DISCUSSION 
This study is the £lIst demonstration ofDBI-LI, a putative endoge-
nous modulator of mitochondrial benzodiazepine receptors and 
fatty acyl-CoA binding protein, in human skin. In normal human 
skin we demonstrated the presence ofDBI-LI in the clear cells of the 
eccrine sweat gland, secretory cells of the sebaceous gland, and in 
granular cells of the epidermis. The peptide was undetectable in 
other cell types of the skin. 
The epidermal location of DBI-LI correlates with the whole-
body autoradiographic localization of the mitochondrial-type ben-
zodiazepine receptors in neonatal rat skin, as demonstrated by An-
holt et 01 [6]' With theLl technique it was not possible to establish 
the localization of the receptors to any distinct epidermal layer or 
dermal adnexes. Further electron microscopic evidence is needed to 
determine whether the intracytoplasmic DBI-LI demonstrated here 
is co-localized w ithin the same cells with MER. However, it has 
been shown that many cells containing DBI are also highly 
enriched in MERs [21) . 
Although DB! is widely distributed in various peripheral tissues, 
it is expressed in each tissue in specialized cells. DB! is highly 
concentrated in steroid producing cells, such as Leydig cells in testis 
and cortical cells of the 3drenal gland [21,25), as well as in cells 
regulating water and electrolyte transport, such as distal convoluted 
duct cells in the kidney [21]. Although the activity of DBI in pe-
ripheral tissues is still far fr0111 clear, there is evidence to show that it 
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Figure 2. Distribution of DBI-Ll in the eccrine sweat gland. a) The secre-
tory coils of the glands ate immunoreactive (asterisks) whereas the ductal 
parts (circles) are unstained. b) A serial section counterstained with hematox-
ylin-eosin. Bar, 50 iJ.m. 
is involved in steroid and cholesterol biosynthesis, water and elec-
trolyte transport, acyl-eoA binding, and glucose-mediated insulin 
release [3,13,16]. In the light of these possible functions, our immu-
nocytochemical findings are of special interest. 
The cells of sebaceous glands exhibited heterogeneous immuno-
reactivity probably corresponding to the narrow cytoplasmic rims 
containing the cell organelles and the lipid synthesis. In the epider-
mis, DBI-LI was restricted to the uppermost layers ofkeratinocytes. 
EspeciaIly the cells of the granular layer were immunoreactive. 
These cells are known to synthesize, contain, and excrete lipids with 
a remarkably high proportion of cholesterol in epidermal lipids 
[28]. One important component for lipid and steroid biosynthesis is 
fatty acyl-CoA (12] and it is possible that DBI via binding acyl-CoA 
stimulates both cholesterol and lipid synthesis. 
Recently DBI-LI has also been localized in the epithelial cells of 
various rat organs that are specialized in water and electrolyte reab-
sorption and secretion, such as epithelial cells of kidney tubules, 
upper intestinal tract, bronchioles, ana choroid plexus and cLIcum-
ventricular organ in the brain (21,25] . Our results demonstrate that 
in the sweat gland, DBI-LI was localized in the clear cells of the 
gland, which are mainly responsible for the secretion of sweat 
[26,27]. 
Our findings suggest that DBl might also be metabolically in-
volved in the synthesizing and secretion process of lipids in kerati-
110cytes. The forming and composition of an epidermal lipid barrier 
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Figure 3. Expression of DBI-LI in human skin at the ultrastrucrurallevcl 
(pre-embedding PAP technique). a) Sweat gland. DBI-immunoactiviry is 
seen in a clear cell while a neighboring cell is negative (asterisks) ,. the immu-
noreactivity is distributed throughout the cell cytoplasm including mit()-
chondria (m) . The nucleus (11) is unstained; bar, 111m. b) Sebaceous gland. 
DBI-LI is distributed throughout the narrow cytoplasmic rim of the cell 
including the mitochondria (m). The sebum (asterisks) is unstained. Bar, 
500 nm. 
as weIJ as the composition of the sebum in the sebaceous glands 
could be modified by the activity of DBl. The demonstration of 
OBI in skin has a special interest because OBI may have multiple 
important functions in skin physiology and pathologic processes in 
metabolically different types of skin disease. 
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